Pyrrolobenzodiazepine Intermediates for Simplified Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of commercially available intermediates for the synthesis of pyrrolobenzodiazepines (PBDs) necessitates scientists to develop each synthesis de novo, which is time-consuming and inefficient.
Innovation Solution
The development of new compounds of formula I, which are useful in the synthesis of PBDs, including specific protecting groups and functional groups that allow for flexible synthetic pathways, such as Suzuki coupling reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If scientists develop each synthesis de novo, then they can create custom PBD payloads, but the process becomes time-consuming and inefficient
Solution Approach 1:
The patent provides pre-synthesized intermediates of formula I that are ready for direct use in PBD payload synthesis. These intermediates have been prepared in advance with various protecting groups (R1, R5) and functional groups (R2-R6) already in place, eliminating the need for scientists to develop syntheses de novo while still allowing customization through selective deprotection and further reactions.
Solution Approach 2:
The intermediates of formula I serve as key building blocks that bridge commercially available starting materials and final PBD payloads. By providing these standardized intermediates with multiple functional groups and protecting groups, the patent enables efficient conversion to various PBD payloads without requiring complete de novo synthesis development.
2Adaptability or versatility
If scientists develop each synthesis de novo, then they can optimize for specific applications, but the manufacturing process becomes complex
Solution Approach 1:
The synthesis process is segmented into modular components through the intermediates of formula I, which contain distinct functional groups (R2-R6) and protecting groups (R1, R5) that can be independently managed. This segmentation allows scientists to focus on specific application optimizations without redesigning the entire synthesis pathway, reducing overall process complexity.
Solution Approach 2:
The intermediates of formula I are designed with multiple functional groups and protecting groups that can be selectively manipulated depending on the desired application. This multi-functionality allows a single intermediate structure to serve multiple purposes in different PBD payload syntheses, reducing the need for application-specific synthesis development.
3Productivity
If new intermediates are provided, then the number of synthesis steps is reduced, but the intermediates must be versatile enough for multiple applications
Solution Approach 1:
The intermediates of formula I are designed with multiple functional groups (R2-R6 including ketones, triflates, alcohols, amines) and protecting groups (R1, R5) that can be selectively manipulated depending on the desired application. This multi-functionality allows a single intermediate structure to serve multiple purposes in different PBD payload syntheses, achieving both productivity improvement and versatility.
Solution Approach 2:
The patent provides intermediates with variable substituents (R1-R6) that can be changed depending on the specific application requirements. By adjusting the protecting groups and functional groups at different positions, the same intermediate framework can be adapted for multiple PBD payload types, maintaining versatility while reducing synthesis steps.
Data Source
AI summary
Pyrrolobenzodiazepine (PBD) intermediates, including useful in the preparation of advanced intermediates. PBDs, and PBD dimers. Such PBD intermediates provide several advantages, including simplified synthesis of desired PBD products, greater substrate compatibility, and safer reaction conditions.